Business

This Undervalued Stock May Be Just What the Doctor Ordered

With Big Pharma shifting its drug development toward a strategic-partnership model, wide-moat Icon PLC's scale makes it one of the few companies capable of bidding on and winning these new contracts.

Advertisement—Continue Reading Below

Share